MedTrace Logo

A STUDY TO COMPARE THE PHARMACOKINETICS OF PF-06835919 IN PARTICIPANTS WITH AND WITHOUT HEPATIC IMPAIRMENT

NCT04193436 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 23

Last updated 2024-02-16

Study results available
· View outcomes & findings →

Summary

The study is proposed to characterize the effect of varying degrees of hepatic impairment on the plasma PK of PF-06835919

Conditions

  • Hepatic Impairment
  • Healthy Participants

Interventions

DRUG

PF-06835919 25 mg

PF-06835919 in 25 mg oral tablet will be administered on Day 1

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
NON_RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-01-21
Primary Completion
2021-07-09
Completion
2021-07-09

Countries

  • Belgium
  • Czechia
  • Slovakia

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04193436 on ClinicalTrials.gov